An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 392-399

  Covey, Lirio S ^a   Hu, Mei Chen ^b   Green, Carla A ^c   Brigham, Gregory ^d   Hurt, Richard D ^e   Adler, Lenard ^f   Winhusen, Theresa ^g  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Mayo Clinic   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Multisite trials; OROS methylphenidate; Site effects; Smokers with ADHD

Indexed keywords

METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL HEALTH CENTER; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); OSMOTIC RELEASE ORAL SYSTEM; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADMINISTRATION, ORAL; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; OSMOTIC PRESSURE; RESEARCH DESIGN; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 80052240544     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596979     Document Type: Article

References (14)

1. Friedman LM, Furberg CD, DeMetz DL. Multicenter trials. In Fundamentals of Clinical Trials. St. Louis, MO: Mosby- Yearbook, Inc., 1985; 285-298.
2. Nunes EV, Ball S, Booth R, Brigham G, Calsyn DA, Carroll K, Feaster DJ, Hien D, Hubbard RL, Ling W, Petry NM, Rotrosen J, Selzer J, Stitzer M, Tross S, Wakim P, Winhusen T,Woody G. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs? J Subst Abuse Treat 2010; 38(Suppl. 1):S97-S112.
3. Ioannidis JPA, Dixon DO, McIntosh M, Albert JM, Bozzette SA, Schnittman SM. Relationship between event rates and treatment effects in clinical site differences within multicenter trials: An example from Primary Pneumocystis carinii Prophylaxis. Control Clin Trials 1999; 20:253-266. (Pubitemid 29219505)
4. Kraemer HC. Pitfalls of randomized clinical trials of efficacy and effectiveness. Schizophr Bull 2000; 26: 533-541.
5. March J, Kraemer HC, Trivedi M, Csernansky J, Davis J, Ketter TA, Glick ID. What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology 2010; 35:2491-2501.
6. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM. Impact of attentiondeficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71:1680-1688.
7. Adler LA, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 7:187-201. (Pubitemid 38452762)
8. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res 2003; 5: 13-25. (Pubitemid 36285465)
9. Sobell LC, Sobell MB. (1992). Timeline Follow-back: A technique for assessing self-reported ethanol consumption. In Allen J, Litten RZ, (Eds.), Measuring Alcohol Consumption: Psychosocial and Biological Methods (pp. 41-72). Totowa, NJ: Humana Press.
10. Jarvis MJ, Tunsall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests to distinguish smokers from nonsmokers. Am J Publ Health 1987; 77:1435-1438. (Pubitemid 18011591)
11. Adler LA, Spencer T, Faraone SV. Training raters to assess adult ADHD: Reliability ratings. J Atten Disord 2005; 8: 121-126. (Pubitemid 40805795)
12. Moolchan ET, Radzius A, Epstein DH, Uhl G, Gorelick DA, Cadet JL, Henningfield JE. The Fagerstrom test for nicotine dependence and the diagnostic interview schedule: Do they diagnose the same smokers? Addict Behav 2002; 27:101-113. (Pubitemid 34031734)
13. Brown H, Prescott, R. Applied Mixed Models in Medicine (2nd ed.). Hoboken, NJ: John Wiley & Sons, 2006.
14. Berlin I, Chen H, Covey LS. Depressive mood, suicide ideation, and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. Addiction 2010; 105:2209-2216.